Tempest Therapeutics Appoints Drake Richey and John Yee to Board

Tempest Therapeutics appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its Board of Directors effective June 4, 2026. The appointments bring financial advisory and therapeutic product development expertise as the company advances its CAR-T cell therapy pipeline for cancer treatment.